Gordon Wishart

Professor Gordon Wishart is the former Director of the Cambridge Breast Unit from 2005-2010, and current Visiting Professor of Cancer Surgery at Anglia Ruskin University since 2008. He has a strong track record in clinical research, with more than 100 peer-reviewed papers in scientific journals. In 2010 he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, now used worldwide.

Professor Wishart is also the founder, CEO & Chief Medical Officer of Cambridge-based Check4Cancer, a leading early cancer detection company. In 2016 Check4Cancer launched rapid access, streamlined and audited diagnostic pathways for breast and skin cancer to the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. Check4Cancer has recently developed cancer risk assessment and impact models that underpin risk-stratified cancer screening programmes, with education and behavioural change at the centre of a cancer prevention strategy, resulting in the 2022 Laing Buisson “Innovation in Health Tech” award for the MyCancerRisk programme.